Compugen (CGEN) Competitors $1.64 -0.07 (-4.09%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CGEN vs. BDTX, CHRS, INBX, TCRR, ITOS, CRMD, NUVB, QTTB, CRVS, and MREOShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Black Diamond Therapeutics (BDTX), Coherus BioSciences (CHRS), Inhibrx (INBX), TCR2 Therapeutics (TCRR), iTeos Therapeutics (ITOS), CorMedix (CRMD), Nuvation Bio (NUVB), Q32 Bio (QTTB), Corvus Pharmaceuticals (CRVS), and Mereo BioPharma Group (MREO). These companies are all part of the "medical" sector. Compugen vs. Black Diamond Therapeutics Coherus BioSciences Inhibrx TCR2 Therapeutics iTeos Therapeutics CorMedix Nuvation Bio Q32 Bio Corvus Pharmaceuticals Mereo BioPharma Group Compugen (NASDAQ:CGEN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Which has preferable earnings and valuation, CGEN or BDTX? Compugen has higher revenue and earnings than Black Diamond Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$33.46M4.37-$18.75M-$0.10-16.40Black Diamond TherapeuticsN/AN/A-$82.44M-$1.50-1.99 Does the MarketBeat Community prefer CGEN or BDTX? Compugen received 258 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.44% of users gave Black Diamond Therapeutics an outperform vote while only 64.30% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30864.30% Underperform Votes17135.70% Black Diamond TherapeuticsOutperform Votes5069.44% Underperform Votes2230.56% Does the media favor CGEN or BDTX? In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Black Diamond Therapeutics and 2 mentions for Compugen. Compugen's average media sentiment score of 1.10 beat Black Diamond Therapeutics' score of 0.31 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CGEN or BDTX more profitable? Compugen's return on equity of -16.10% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CompugenN/A -16.10% -9.23% Black Diamond Therapeutics N/A -69.08%-51.68% Do analysts rate CGEN or BDTX? Compugen currently has a consensus price target of $4.00, suggesting a potential upside of 143.90%. Black Diamond Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 418.39%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in CGEN or BDTX? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, CGEN or BDTX? Compugen has a beta of 2.64, indicating that its share price is 164% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. SummaryCompugen beats Black Diamond Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.35M$3.11B$5.10B$8.43BDividend YieldN/A1.76%7.52%4.16%P/E Ratio-16.4015.54133.4116.50Price / Sales4.37296.271,617.6575.90Price / CashN/A144.3537.2033.56Price / Book2.253.994.594.98Net Income-$18.75M-$42.25M$116.16M$224.69M7 Day Performance-1.80%-0.25%-0.97%-0.51%1 Month Performance-10.38%8.21%5.32%3.32%1 Year Performance120.96%28.26%33.76%25.51% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.1663 of 5 stars$1.64-4.1%$4.00+143.9%+121.0%$146.35M$33.46M-16.4068Upcoming EarningsNews CoveragePositive NewsGap DownBDTXBlack Diamond Therapeutics2.1854 of 5 stars$2.99+3.5%$15.50+418.4%+57.4%$168.97MN/A-1.9990CHRSCoherus BioSciences3.6918 of 5 stars$0.67-6.9%$7.13+963.4%-81.4%$77.19M$308.13M-1.67246Upcoming EarningsINBXInhibrx3.6726 of 5 stars$15.55-1.6%$27.00+73.6%-14.7%$225.16M$1.63M0.00166Upcoming EarningsNews CoverageTCRRTCR2 TherapeuticsN/A$1.48-5.7%N/A+0.0%$58.11MN/A-0.35137High Trading VolumeITOSiTeos Therapeutics2.31 of 5 stars$8.97+1.8%$30.50+240.0%-13.2%$327.58M$12.60M-2.9990Positive NewsCRMDCorMedix2.4783 of 5 stars$9.59-4.0%$15.20+58.5%+174.8%$581.89M$12.26M-11.8430Earnings ReportAnalyst UpgradeHigh Trading VolumeNUVBNuvation Bio3.4959 of 5 stars$2.29-0.4%$6.40+179.5%+69.6%$573.26MN/A-1.0960Upcoming EarningsQTTBQ32 Bio1.9129 of 5 stars$46.84-1.2%$72.33+54.4%N/A$564.89M$-6,651,000.00-2.0339Upcoming EarningsHigh Trading VolumeCRVSCorvus Pharmaceuticals1.5763 of 5 stars$9.02-0.9%$10.83+20.1%+558.4%$564.20MN/A-20.0430High Trading VolumeMREOMereo BioPharma Group1.7224 of 5 stars$4.01-6.3%$7.50+87.0%+91.9%$562.43M$1M0.0040News Coverage Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Coherus BioSciences Alternatives Inhibrx Alternatives TCR2 Therapeutics Alternatives iTeos Therapeutics Alternatives CorMedix Alternatives Nuvation Bio Alternatives Q32 Bio Alternatives Corvus Pharmaceuticals Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGEN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
